ORAMED PHARMACEUTICALS INC. Quarterly Research and Development Expense in USD from Q4 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
Oramed Pharmaceuticals Inc. quarterly/annual Research and Development Expense history and growth rate from Q4 2010 to Q3 2024.
  • Oramed Pharmaceuticals Inc. Research and Development Expense for the quarter ending September 30, 2024 was $2.24M, a 134% increase year-over-year.
  • Oramed Pharmaceuticals Inc. Research and Development Expense for the twelve months ending September 30, 2024 was $6.63M, a 59.2% decline year-over-year.
  • Oramed Pharmaceuticals Inc. annual Research and Development Expense for 2023 was $8.97M, a 67.5% decline from 2022.
  • Oramed Pharmaceuticals Inc. annual Research and Development Expense for 2022 was $27.6M, a 31.7% increase from 2021.
  • Oramed Pharmaceuticals Inc. annual Research and Development Expense for 2021 was $21M, a 105% increase from 2020.
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $6.63M $2.24M +$1.29M +134% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $5.34M $1.44M -$379K -20.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $5.72M $1.18M -$3.25M -73.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $8.97M $1.77M -$7.27M -80.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 $16.2M $957K -$4.39M -82.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $20.6M $1.82M -$7.36M -80.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $28M $4.43M -$1.41M -24.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $29.4M $9.04M $0 0% Sep 1, 2022 Dec 31, 2022 10-K 2023-03-06
Q3 2022 $29.4M $5.35M -$739K -12.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $30.1M $9.18M +$5.98M +187% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $24.2M $5.84M -$332K -5.38% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $24.5M $9.04M +$2.15M +31.2% Sep 1, 2021 Dec 31, 2021 10-QT 2022-03-30
Q3 2021 $22.3M $6.09M +$3.12M +105% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $19.2M $3.2M +$1.27M +66.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $18M $6.17M +$2.85M +85.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $15.1M $6.89M +$4.87M +241% Sep 1, 2020 Dec 31, 2020 10-QT 2022-03-30
Q3 2020 $10.2M $2.97M +$768K +34.9% Jun 1, 2020 Aug 31, 2020 10-K 2021-11-24
Q2 2020 $9.47M $1.93M -$1.94M -50.1% Mar 1, 2020 May 31, 2020 10-Q 2021-07-14
Q1 2020 $11.4M $3.32M +$206K +6.62% Dec 1, 2019 Feb 29, 2020 10-Q 2021-04-13
Q4 2019 $11.2M $2.02M -$2.33M -53.5% Sep 1, 2019 Nov 30, 2019 10-Q 2021-01-14
Q3 2019 $13.5M $2.2M -$534K -19.5% Jun 1, 2019 Aug 31, 2019 10-K 2020-11-24
Q2 2019 $14.1M $3.86M -$333K -7.94% Mar 1, 2019 May 31, 2019 10-Q 2020-07-07
Q1 2019 $14.4M $3.11M +$390K +14.3% Dec 1, 2018 Feb 28, 2019 10-Q 2020-04-06
Q4 2018 $14M $4.35M +$2.02M +86.8% Sep 1, 2018 Nov 30, 2018 10-Q 2020-01-09
Q3 2018 $12M $2.73M +$198K +7.81% Jun 1, 2018 Aug 31, 2018 10-K 2019-11-27
Q2 2018 $11.8M $4.19M +$1.93M +85% Mar 1, 2018 May 31, 2018 10-Q 2019-07-10
Q1 2018 $9.85M $2.72M -$401K -12.8% Dec 1, 2017 Feb 28, 2018 10-Q 2019-04-10
Q4 2017 $10.3M $2.33M -$26K -1.11% Sep 1, 2017 Nov 30, 2017 10-Q 2019-01-14
Q3 2017 $10.3M $2.54M -$7.48M -74.7% Jun 1, 2017 Aug 31, 2017 10-K 2019-11-27
Q2 2017 $17.8M $2.27M +$3.98M Mar 1, 2017 May 31, 2017 10-Q 2018-07-12
Q1 2017 $13.8M $3.13M +$1.82M +140% Dec 1, 2016 Feb 28, 2017 10-Q 2018-04-09
Q4 2016 $12M $2.35M +$4.25M Sep 1, 2016 Nov 30, 2016 10-Q 2018-01-11
Q3 2016 $7.71M $10M +$8.59M +601% Jun 1, 2016 Aug 31, 2016 10-K 2018-11-28
Q2 2016 -$880K -$1.71M -$2.63M -287% Mar 1, 2016 May 31, 2016 10-Q 2017-07-06
Q1 2016 $1.75M $1.3M +$167K +14.7% Dec 1, 2015 Feb 29, 2016 10-Q 2017-04-05
Q4 2015 $1.58M -$1.9M -$3.2M -246% Sep 1, 2015 Nov 30, 2015 10-Q 2017-01-11
Q3 2015 $4.78M $1.43M -$1.51M -51.5% Jun 1, 2015 Aug 31, 2015 10-K 2017-11-29
Q2 2015 $6.3M $915K +$2M Mar 1, 2015 May 31, 2015 10-Q 2016-07-06
Q1 2015 $4.29M $1.14M +$462K +68.5% Dec 1, 2014 Feb 28, 2015 10-Q 2016-04-06
Q4 2014 $3.83M $1.3M +$552K +73.6% Sep 1, 2014 Nov 30, 2014 10-Q 2016-01-13
Q3 2014 $3.28M $2.94M +$7.19M Jun 1, 2014 Aug 31, 2014 10-K 2016-11-25
Q2 2014 -$3.91M -$1.09M -$1.92M -230% Mar 1, 2014 May 31, 2014 10-Q 2015-07-01
Q1 2014 -$1.99M $674K -$75K -10% Dec 1, 2013 Feb 28, 2014 10-Q 2015-04-03
Q4 2013 -$1.91M $750K +$357K +91% Sep 1, 2013 Nov 30, 2013 10-Q 2015-01-08
Q3 2013 -$2.27M -$4.25M -$4.79M -892% Jun 1, 2013 Aug 31, 2013 10-K 2015-11-25
Q2 2013 $2.51M $836K +$586K +235% Mar 1, 2013 May 31, 2013 10-Q 2014-07-14
Q1 2013 $1.93M $749K +$38.3K +5.4% Dec 1, 2012 Feb 28, 2013 10-Q 2014-04-10
Q4 2012 $1.89M $393K +$209K +113% Sep 1, 2012 Nov 30, 2012 10-Q 2014-01-14
Q3 2012 $1.68M $537K +$246K +84.9% Jun 1, 2012 Aug 31, 2012 10-K 2014-11-14
Q2 2012 $1.43M $250K +$8.4K +3.48% Mar 1, 2012 May 31, 2012 10-Q 2013-07-17
Q1 2012 $1.43M $711K +$369K +108% Dec 1, 2011 Feb 29, 2012 10-Q 2013-04-11
Q4 2011 $1.06M $184K -$102K -35.8% Sep 1, 2011 Nov 30, 2011 10-Q 2012-12-26
Q3 2011 $1.16M $290K Jun 1, 2011 Aug 31, 2011 10-K 2012-12-12
Q2 2011 $241K Mar 1, 2011 May 31, 2011 10-Q 2012-07-12
Q1 2011 $341K Dec 1, 2010 Feb 28, 2011 10-Q 2012-04-04
Q4 2010 $286K Sep 1, 2010 Nov 30, 2010 10-Q 2012-01-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.